Manufacturing an mRNA vaccine is a multi-stage biochemical assembly line that starts with a strand of engineered DNA and ends with billions of tiny fat-coated particles ready for injection. Unlike traditional vaccines, which grow viruses in eggs or cell cultures over weeks or months, the mRNA process is entirely cell-free after the initial template production step. That distinction is what made the technology fast enough to respond to a pandemic, but the chemistry behind each stage is precise, tightly controlled, and still being refined.
Building the DNA Blueprint
Every mRNA vaccine begins with a DNA template. This template carries the genetic sequence encoding the target protein, such as the spike protein of a coronavirus. To produce that template at scale, manufacturers typically insert the desired gene sequence into a circular piece of DNA called a plasmid, then grow it inside bacteria. The bacteria act as tiny copying machines, replicating the plasmid millions of times over. A typical production run involves fermenting engineered E. coli in a bioreactor, then cracking the cells open and pulling out the plasmid DNA through a series of purification steps.1Molecular Therapy Nucleic Acids. Supercoiled DNA percentage: A key in-process control of linear DNA template for mRNA drug substance manufacturing The resulting material has to meet strict quality standards before it can be used as a starting material for clinical-grade vaccine production.2PubMed. Producing Plasmid DNA Template for Clinical Grade RNA Vaccine Manufacture
Once the plasmid is purified, it needs to be cut open. Plasmid DNA is circular, but the transcription reaction that follows requires a linear template with a defined start and stop point. Manufacturers use restriction enzymes to cut the circle at a precise location, producing a clean linear strand. The quality of this linearization matters: leftover circular DNA or fragments can generate unwanted RNA products downstream.
In Vitro Transcription, the Core Reaction
The heart of mRNA manufacturing is a reaction called in vitro transcription, or IVT. In a bioreactor, the linear DNA template is mixed with an enzyme called T7 RNA polymerase, free nucleotide building blocks, and buffer salts. The polymerase reads the DNA and assembles a complementary mRNA strand, one nucleotide at a time. This is conceptually the same thing your cells do when they read a gene, but it happens in a test tube rather than inside a living organism.3PubMed. Enhancing mRNA vaccine production: Optimization of in vitro transcription for improved yield and purity
The IVT step is deceptively simple in concept but tricky in practice. The reaction conditions, including temperature, magnesium concentration, and the ratio of enzyme to template, all affect how much usable mRNA you get versus how much junk accumulates. One of the biggest headaches is the tendency of T7 RNA polymerase to produce double-stranded RNA (dsRNA) as a byproduct. This happens when the enzyme doubles back on a finished strand and copies it in reverse, creating a hairpin or duplex. dsRNA is a potent trigger of the innate immune system, so even small amounts can cause unwanted inflammatory side effects in the final vaccine. Some manufacturers have turned to engineered versions of the polymerase or optimized transcription conditions to reduce dsRNA formation from the start.4PubMed Central. Process and analytical strategies for the safe production of mRNA vaccines and therapeutics
Adding the Cap and Tail
A raw mRNA strand fresh out of the IVT reaction is not ready for use. Human cells would recognize it as foreign and degrade it within minutes. To make the mRNA look like a natural cellular message, two chemical features need to be added: a cap at the front end and a poly-A tail at the back.
The 5′ cap is a modified nucleotide structure that sits on the leading edge of the mRNA. In living cells, capping is essential for the ribosome, the cell’s protein-making machine, to latch onto the mRNA and begin translating it into protein. Without a proper cap, the mRNA is also rapidly chewed up by enzymes. Manufacturers add the cap either during the IVT reaction itself, by including cap analogs in the nucleotide mix, or in a separate enzymatic step afterward. Each approach has trade-offs in efficiency, cost, and the percentage of mRNA molecules that end up properly capped.5PubMed Central. mRNA capping: biological functions and applications
The poly-A tail, a long string of adenine nucleotides at the 3′ end, protects the mRNA from degradation and also helps with translation efficiency. The tail can be encoded directly into the DNA template, so it is transcribed automatically during IVT, or it can be added enzymatically after transcription. Encoding it in the template gives more consistent tail lengths, which matters because tail length influences how long the mRNA survives inside a cell.
Swapping in Modified Nucleosides
One of the breakthroughs that made mRNA vaccines practical was the discovery that swapping in chemically modified nucleosides dramatically reduces the immune system’s alarm response to synthetic mRNA. In both the Pfizer-BioNTech and Moderna COVID-19 vaccines, every uridine nucleotide in the mRNA is replaced with N1-methylpseudouridine (m1Ψ). This modified building block changes the shape and hydrogen-bonding pattern of the nucleotide just enough that immune sensors like TLR7, which patrol for foreign single-stranded RNA, fail to recognize it.6ACS Central Science. Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines
The modification is introduced during the IVT step itself: manufacturers simply supply m1Ψ-triphosphate in place of standard UTP in the nucleotide mix, and the polymerase incorporates it throughout the strand. The result is an mRNA molecule that looks natural enough to be translated efficiently by ribosomes but avoids triggering a strong innate inflammatory reaction before the adaptive immune response has a chance to develop.
Purification and Removing Double-Stranded RNA
After the IVT reaction, the mRNA product is contaminated with leftover DNA template, free nucleotides, enzyme proteins, and the dsRNA byproducts mentioned earlier. All of these need to be removed. The DNA template is typically digested with DNase enzymes, and then the mixture goes through a series of chromatography and filtration steps.
Removing dsRNA is one of the most critical purification challenges. Even trace amounts can activate innate immune pathways and reduce the vaccine’s tolerability. Manufacturers use a range of chromatographic strategies, including reversed-phase ion-pairing chromatography, cellulose-based purification, and specialized dsRNA-binding resins.7Journal of Chromatography A. Removing immunogenic double-stranded RNA impurities post in vitro transcription synthesis for mRNA therapeutics production: A review of chromatography strategies Size-exclusion chromatography has also been demonstrated as an effective lab-scale method, achieving clear separation between dsRNA and the target mRNA with high recovery of the desired product.8PubMed. Purification of Double-Stranded RNA Impurities From In Vitro-Transcribed mRNA Using Size-Exclusion Chromatography No single purification method dominates the industry; different manufacturers use different combinations depending on their scale, equipment, and tolerance for process complexity.
Wrapping the mRNA in Lipid Nanoparticles
Naked mRNA injected into muscle tissue would be destroyed by enzymes almost instantly and could not cross cell membranes on its own. The solution is to package it inside lipid nanoparticles, or LNPs: tiny spheres roughly 100 nanometers across, made of a carefully chosen blend of fats. A typical LNP formulation contains four components: an ionizable lipid, a helper lipid, cholesterol, and a PEG-lipid that coats the outer surface.9American Chemical Society. Ionizable Lipid Nanoparticles for mRNA Delivery: Internal Self-Assembled Inverse Mesophase Structure and Endosomal Escape
The ionizable lipid is the key ingredient. It carries a positive charge at low pH, which lets it bind the negatively charged mRNA during the mixing step. Once injected and taken up by a cell, the LNP is pulled into an endosome, a small acidic compartment inside the cell. The drop in pH causes the ionizable lipid to become positively charged again, disrupting the endosomal membrane and releasing the mRNA into the cell’s cytoplasm, where ribosomes can translate it into protein. The ionizable lipids used in the Pfizer-BioNTech and Moderna vaccines, ALC-0315 and SM-102 respectively, have similar chemical architectures built around tertiary amine groups linked to saturated fatty chains via ester bonds.9American Chemical Society. Ionizable Lipid Nanoparticles for mRNA Delivery: Internal Self-Assembled Inverse Mesophase Structure and Endosomal Escape
The actual mixing step, where mRNA meets lipids, happens through microfluidic devices or specialized mixers. An ethanol solution containing the dissolved lipids is rapidly combined with an aqueous solution containing the mRNA. The speed and turbulence of mixing are critical: they control the size and uniformity of the resulting nanoparticles.10PubMed. Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications Under well-mixed conditions, the LNPs self-assemble into particles close to 100 nm in diameter with electron-dense core structures visible under cryo-electron microscopy.11Scientific Reports. Optimal self-assembly of lipid nanoparticles (LNP) in a ring micromixer After mixing, the ethanol is removed by dilution and filtration, and the formulation is concentrated to the target mRNA dose.
Quality Control and Analytical Testing
Before any batch of mRNA vaccine is released, it undergoes extensive analytical testing. The list of attributes that need to be measured is long: mRNA identity and sequence integrity, percentage of molecules that are properly capped, poly-A tail length, overall RNA purity, residual DNA content, dsRNA levels, LNP size and uniformity, encapsulation efficiency, endotoxin levels, and sterility. The analytical toolkit includes electrophoresis, liquid chromatography, mass spectrometry, and sequencing technologies.12PubMed Central. Current Analytical Strategies for mRNA-Based Therapeutics
One metric that attracted public attention during the pandemic was the amount of residual DNA left in the final product. Because the mRNA is made from a DNA template, trace quantities of that template DNA can carry through purification. Independent testing confirmed that the DNA-to-RNA mass ratio in approved vaccines is around 1 to 1,000, consistent with the product specifications. Earlier claims of vastly higher DNA contamination levels were shown to be artifacts of the measurement conditions used, specifically unusually high RNA and lipid concentrations in those experiments.13PubMed. Quantification of objective concentrations of DNA impurities in mRNA vaccines
Encapsulation efficiency, the percentage of mRNA molecules actually enclosed inside LNPs rather than floating free in solution, is another important quality attribute. Free mRNA is less effective and more prone to degradation. Anion exchange chromatography has been developed as a way to separate LNPs from free mRNA based on their charge differences, offering a direct measurement of encapsulation.14PubMed Central. Anion Exchange Chromatography to Determine mRNA Encapsulation in Lipid Nanoparticles
The Cold Chain Problem
mRNA is inherently fragile. Unlike DNA, which is a fairly rugged molecule, mRNA degrades quickly when exposed to heat, enzymes, or even the hydroxyl groups in water. Wrapping it in LNPs helps, but the finished vaccine still needs to be kept cold. The Pfizer-BioNTech vaccine initially required ultra-cold storage at around minus 70°C, which created enormous logistical challenges for distribution, particularly in low-income countries without deep-freeze infrastructure.
Freeze-drying, or lyophilization, is one promising solution. Researchers have demonstrated that nucleoside-modified mRNA-LNPs can be lyophilized into a dry powder that maintains its physical properties and biological activity for at least 12 weeks at room temperature and at least 24 weeks at refrigerator temperature. In mouse studies, the freeze-dried vaccine produced the same level of immune response as freshly prepared liquid formulation.15PubMed Central. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine If lyophilized mRNA vaccines reach commercial scale, they could dramatically simplify global distribution.
Supply Chain Bottlenecks
Building an mRNA vaccine requires a surprisingly narrow set of specialized raw materials. Unlike traditional vaccine production, which relies on widely available biological culture media, mRNA manufacturing depends on high-purity plasmid DNA, modified nucleotides, capping reagents, T7 RNA polymerase, and the four lipid components for LNP formulation. Only a handful of global suppliers produce these materials at pharmaceutical grade.16PubMed Central. Unpacking the mRNA Supply Chain: Challenges and Opportunities for Global Health
During the COVID-19 pandemic, this concentration became a serious vulnerability. Demand for modified nucleotides and ionizable lipids surged far beyond existing capacity, and some manufacturers had to wait months for deliveries. The situation highlighted a structural weakness: the mRNA platform’s speed advantage in design and development can be bottlenecked by its dependence on specialty chemicals that take time to scale up. Efforts to diversify the supplier base and build regional manufacturing capacity, such as BioNTech’s modular BioNTainer facilities, are underway but still face regulatory and technical challenges.17PubMed Central. Advancements and challenges in next-generation mRNA vaccine manufacturing systems
Moving Toward Continuous Manufacturing
Most mRNA vaccine manufacturing today operates in batch mode: each step is completed, tested, and handed off to the next. This is reliable but slow. One area of active development is continuous end-to-end production, where the entire process from cell lysis through LNP formulation runs without interruption. A feasibility study of continuous mRNA manufacturing found that the process is technically achievable, with a minimum selling price per dose calculated at roughly €1.30 to €1.45. The study also identified the two most resource-intensive steps: cell lysis for plasmid recovery and the enzymes used for template linearization, which together accounted for about 40% of equipment and raw material costs.18PubMed Central. Pharma 4.0 Continuous mRNA Drug Products Manufacturing
Continuous manufacturing could eventually bring down costs, improve consistency, and make it easier to ramp production up or down in response to demand. But it also demands sophisticated real-time process monitoring and control systems that the industry is still developing.
Cell-Free DNA Templates
One of the most promising shifts in mRNA manufacturing is the move away from bacteria-based plasmid production entirely. Cell-free DNA synthesis methods can generate linear DNA templates directly through enzymatic processes like rolling circle amplification, without ever growing bacteria. This eliminates the need for fermentation, cell lysis, and the associated purification steps. It also avoids bacterial backbone sequences in the final template, which simplifies regulatory compliance.19PubMed Central. Synthetic DNA vaccine platform elicits potent immunity where electroporated naked-mRNA is non-immunogenic
PCR-based approaches to template production have also been described. These cell-free, PCR-generated templates can be made quickly and at lower cost than plasmid-based methods, which is appealing for rapid-response scenarios and early-stage development work.20PubMed. PCR-generated DNA templates enable efficient, rapid, and cost-effective mRNA synthesis However, because cell-free methods skip the circular plasmid intermediate, manufacturers need tight controls to ensure the integrity of the linear DNA going into the IVT reaction.1Molecular Therapy Nucleic Acids. Supercoiled DNA percentage: A key in-process control of linear DNA template for mRNA drug substance manufacturing
Self-Amplifying RNA and the Next Manufacturing Frontier
Standard mRNA vaccines deliver a fixed number of mRNA copies per dose. Each copy is translated into protein a limited number of times and then degraded. Self-amplifying RNA (saRNA) takes a different approach: it encodes not just the target antigen but also a replicase enzyme that copies the RNA inside the transfected cell. This means a single saRNA molecule can generate many more copies of itself after delivery, potentially allowing much lower doses to achieve the same or stronger immune response.21PubMed Central. Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19
From a manufacturing standpoint, lower doses per person would mean each production batch serves many more people, easing supply constraints. saRNA constructs also produce higher cumulative protein expression and longer expression duration compared to conventional mRNA at equivalent doses.22PubMed. Self-Amplifying RNA-Based Therapeutics: Advances, Challenges, and Future Perspectives The trade-off is that saRNA molecules are much larger than standard mRNA, roughly three to four times the length, which makes the IVT reaction less efficient and the purification more demanding. The larger size also affects LNP encapsulation. Japan approved the first saRNA vaccine in late 2023, and several others are in clinical development, so the manufacturing challenges are clearly solvable, if not yet fully optimized.
Environmental Footprint of mRNA Production
The mRNA vaccine process uses substantial quantities of solvents, buffers, and single-use plastic consumables. Life cycle assessments have found that one of the most environmentally impactful steps is tangential flow filtration, a membrane-based concentration and buffer-exchange step used multiple times during purification. The large volumes of solvent consumed and waste generated at this stage, along with buffer reagents like sodium citrate, drive a significant portion of the process’s environmental impact across multiple categories. Implementing recycling loops for buffer solutions and solvents can reduce those impacts by roughly 10% while also cutting operating costs by about 13%.23Elsevier. Technoeconomic and Life Cycle Assessment of an mRNA Vaccine Integrated Manufacturing Plant
Compared to egg-based influenza vaccine production, mRNA manufacturing has a smaller physical footprint and shorter production timelines, which carries inherent sustainability advantages. But the dependence on single-use bioreactor bags, plastic tubing, and specialized chemical reagents creates a waste profile that the industry is only beginning to address systematically. As mRNA vaccines expand beyond pandemic response into routine immunization schedules, the environmental calculus will become harder to ignore.